1. Home
  2. LITB vs LTRN Comparison

LITB vs LTRN Comparison

Compare LITB & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LITB
  • LTRN
  • Stock Information
  • Founded
  • LITB 2007
  • LTRN 2013
  • Country
  • LITB Singapore
  • LTRN United States
  • Employees
  • LITB N/A
  • LTRN N/A
  • Industry
  • LITB Catalog/Specialty Distribution
  • LTRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • LITB Consumer Discretionary
  • LTRN Health Care
  • Exchange
  • LITB Nasdaq
  • LTRN Nasdaq
  • Market Cap
  • LITB N/A
  • LTRN 46.7M
  • IPO Year
  • LITB N/A
  • LTRN 2020
  • Fundamental
  • Price
  • LITB $1.00
  • LTRN $3.74
  • Analyst Decision
  • LITB
  • LTRN Hold
  • Analyst Count
  • LITB 0
  • LTRN 1
  • Target Price
  • LITB N/A
  • LTRN N/A
  • AVG Volume (30 Days)
  • LITB 21.6K
  • LTRN 47.1K
  • Earning Date
  • LITB 03-24-2025
  • LTRN 05-08-2025
  • Dividend Yield
  • LITB N/A
  • LTRN N/A
  • EPS Growth
  • LITB N/A
  • LTRN N/A
  • EPS
  • LITB N/A
  • LTRN N/A
  • Revenue
  • LITB $333,093,000.00
  • LTRN N/A
  • Revenue This Year
  • LITB N/A
  • LTRN N/A
  • Revenue Next Year
  • LITB N/A
  • LTRN N/A
  • P/E Ratio
  • LITB N/A
  • LTRN N/A
  • Revenue Growth
  • LITB N/A
  • LTRN N/A
  • 52 Week Low
  • LITB $0.91
  • LTRN $2.79
  • 52 Week High
  • LITB $6.00
  • LTRN $11.99
  • Technical
  • Relative Strength Index (RSI)
  • LITB 41.05
  • LTRN 42.37
  • Support Level
  • LITB $0.92
  • LTRN $3.40
  • Resistance Level
  • LITB $1.05
  • LTRN $4.00
  • Average True Range (ATR)
  • LITB 0.05
  • LTRN 0.33
  • MACD
  • LITB 0.01
  • LTRN -0.04
  • Stochastic Oscillator
  • LITB 61.54
  • LTRN 32.11

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Share on Social Networks: